Disclaimer Research Use Only (RUO) NovaCell legal disclaimer: all peptides are sold strictly for in-vitro biochemical research
medRxiv , 2023.2004.2013.23288227 (2023)
Ceftriaxone alleviates early brain injury after subarachnoid hemorrhage by increasing excitatory amino acid transporter 2 expression via the PI3K/Akt/NF-B signaling pathway
A method of preventing gait abnormalities in a patient with Parkinson's disease or of improving or restoring to normal the gait of a patient with Parkinson's disease, comprising the step of administering to said patient an amount of one or more hepatocyte growth factor mimics sufficient to prevent, improve or restore to normal said gait, said one or more hepatocyte growth factor mimics having a general structural formula 1 2 3 where Ri is one of an N-acyl group, a substituted or unsubstituted phenyl, a norleucine group, and an amino acid selected from tyrosine, phenylalanine, aspartic acid, arginine, isoleucine, serine, histidine, glycine, cysteine, methionine, tryptophan, lysine norvaline, ornithine, and s-benzyl cysteine
